Synosia Therapeutics develops and intends to commercialise innovative products for unmet medical needs in psychiatry and neurology. We are working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with
Novartis,
Roche and
Syngenta, into new indications with significant potential.
Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. We are backed by $62 million in funding from high-quality investors and have a rich portfolio of compounds.
PRINT THIS PAGE